Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext

• Main Authors: A. L. Bakulev (Author), A. V. Samtsov (Author), A. A. Kubanov (Author), V. R. Khairutdinov (Author), M. M. Kokhan (Author), A. V. Artemyeva (Author), S. I. Derbin (Author), E. V. Chernyaeva (Author), R. A. Ivanov (Author)
• Format: Book
• Published: State Scientific Center of Dermatovenereology and Cosmetology, 2019-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Netakimabis original monoclonal antibody against IL-17. This article outlines the key results of a phase II open-label extension trial of netakimab 80 mg and 120 mg in patients with moderate-to-severe psoriasis.The main aim of the trial is to estimate efficacy, safety and immunogenicity of long-term...